SUBSEQUENT EVENTS	9 Months Ended
Sep. 30, 2025
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 17 – SUBSEQUENT EVENTS Ortho-Tain Litigation Settlement As previously disclosed, on June 5, 2020, we filed suit against Ortho-Tain, Inc. (“Ortho-Tain”) in the United States District Court for the District of Colorado seeking relief from certain false, threatening, and defamatory statements to our business affiliate, Benco Dental (“Benco”). As of the date of this Report, the parties are engaging in mediation and settlement discussions, although no assurances can be given that a final settlement will be reached. New Shelf Registration Statement and At The Market Offering On October 24, 2025, the Company filed a prospectus supplement to update the maximum amount of Shares which the Company may under the New Shelf Registration pursuant to General Instruction I.B.6 of Form S-3. As a result of these limitations and the then current market value of the Common Stock held by non-affiliates of the Company, and in accordance with the terms of the ATM Sales Agreement, we may offer and sell Shares having an aggregate offering price of up to $3,583,686 from time to time through Wainwright, which does not include the Shares having an aggregate sales price of approximately $4,605,773 that were sold pursuant to the Prior Shelf Registration to date. During October and November 2025, the Company sold 681,337 Shares at an average price of $3.20 per share through its ATM Sales Agreement, resulting in proceeds of $2.1 million net of commissions. Under the ATM Sales Agreement, $4.7 million of Shares remain available for future sales as of the date of this filing; however, the Company is not obligated to make any sales under this program. Increase in Size of 2024 Omnibus Plan On November 4, 2025, the Company conducted its 2025 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders approved and adopted an amendment to the 2024 Omnibus Plan to increase the number of shares of our Common Stock authorized to be issued pursuant to the 2024 Omnibus Plan from 1,600,000 shares to 4,100,000 shares in the aggregate.

SUBSEQUENT EVENTS

9 Months Ended

Sep. 30, 2025

NOTE 17 – SUBSEQUENT EVENTS

Ortho-Tain Litigation Settlement

As previously disclosed, on June 5, 2020, we filed suit against Ortho-Tain, Inc. (“Ortho-Tain”) in the United States District Court for the District of Colorado seeking relief from certain false, threatening, and defamatory statements to our business affiliate, Benco Dental (“Benco”). As of the date of this Report, the parties are engaging in mediation and settlement discussions, although no assurances can be given that a final settlement will be reached.

New Shelf Registration Statement and At The Market Offering

On October 24, 2025, the Company filed a prospectus supplement to update the maximum amount of Shares which the Company may under the New Shelf Registration pursuant to General Instruction I.B.6 of Form S-3. As a result of these limitations and the then current market value of the Common Stock held by non-affiliates of the Company, and in accordance with the terms of the ATM Sales Agreement, we may offer and sell Shares having an aggregate offering price of up to $3,583,686 from time to time through Wainwright, which does not include the Shares having an aggregate sales price of approximately $4,605,773 that were sold pursuant to the Prior Shelf Registration to date.

During October and November 2025, the Company sold 681,337 Shares at an average price of $3.20 per share through its ATM Sales Agreement, resulting in proceeds of $2.1 million net of commissions. Under the ATM Sales Agreement, $4.7 million of Shares remain available for future sales as of the date of this filing; however, the Company is not obligated to make any sales under this program.

Increase in Size of 2024 Omnibus Plan

On November 4, 2025, the Company conducted its 2025 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders approved and adopted an amendment to the 2024 Omnibus Plan to increase the number of shares of our Common Stock authorized to be issued pursuant to the 2024 Omnibus Plan from 1,600,000 shares to 4,100,000 shares in the aggregate.